Afuresertib
Targeted therapy of multiple myeloma and various solid tumors
- CAS No.
- 1047644-62-1
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Hematology
- Target / Mechanism
- AKT2·AKT3·AKT1
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An oral pan-AKT inhibitor explored in both hematologic and solid tumors, a common targeted candidate within diagnosis-to-treatment integrated pathways.
Oncology / Hematology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Afuresertib is an oral AKT kinase inhibitor that inhibits tumor cell growth by blocking the PI3K-AKT signaling pathway. It is primarily used in targeted therapy research for multiple myeloma and various solid tumors.
Supply source: Unibest · Afuresertib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.